We believe they will improve our earnings-per-share and ultimately enhance our shareholder value.
You need to continue to work on your cost element. But you're not going to save your way to growth. You need to develop products.
I can tell you that reducing the work force by 11 percent, removing $4 billion of ongoing costs from the system and coming up with a new business model to me seems pretty competitive.
I'm confident this first phase of the restructuring plan sets the course for us.
Change is not synonymous with cutting costs.
The problem with an article like that is that we haven't had time to talk to employees. We're very unhappy. We want to tell our employees first.
Do not hoard or panic, ... I see it looking a little better everyday.
For us, it's a gigantic first step.
We are engaged in an ongoing effort to enhance efficiencies throughout the company and improve the way we discover, develop, manufacture and market our medicines and vaccines.
Copyright © 2024 Electric Goat Media. All Rights Reserved.